Clarity Pharmaceuticals Issues 110,000 Shares After Option Exercise and Files Cleansing Notice

Clarity Pharmaceuticals Issues 110,000 Shares Following Option Exercise on 1 July 2026

On 1 July 2026, Clarity Pharmaceuticals confirmed the issuance of 110,000 fully paid ordinary shares resulting from option holders exercising their rights. This share issuance was conducted without formal disclosure under Part 6D.2 of the Corporations Act 2001, a permitted process when accompanied by a subsequent cleansing notice.

The identities of the option holders, the exercise price, and the total proceeds received were not disclosed in this update. Therefore, the exact impact on Clarity's cash reserves cannot be determined from the information provided. However, it is confirmed that 110,000 shares were added to the company's ordinary share capital as of the announcement date.

Implications of the Section 708A Cleansing Notice for On-Sale of Newly Issued Shares

The cleansing notice filed under section 708A(5)(e) of the Corporations Act is a standard legal procedure. Without it, shares issued without a formal prospectus or disclosure document cannot be sold on the market within 12 months of issuance. By lodging this notice, Clarity satisfies statutory requirements that allow recipients of the new shares to trade them freely on the ASX without restriction.

For investors and market participants, this means the 110,000 shares issued via option exercise are now freely tradeable on the secondary market, subject to any individual holder restrictions. The cleansing notice mechanism ensures market integrity by confirming no materially significant undisclosed information exists at the time shares become eligible for on-sale. Clarity has confirmed that no such excluded information exists as of the notice date.

Clarity's Confirmation of Compliance with Continuous Disclosure Requirements Under Chapters 2M, 674, and 674A

In accordance with section 708A(6) of the Corporations Act, Clarity Pharmaceuticals confirmed that as of 1 July 2026, it complies with Chapter 2M of the Corporations Act, which governs financial reporting obligations for Australian companies, including preparation, lodgement, and auditing of financial reports for listed entities.

The company also confirmed adherence to sections 674 and 674A of the Corporations Act, which mandate immediate disclosure of information likely to materially affect the price or value of securities. By affirming compliance, Clarity assures the market that it has fulfilled its ongoing disclosure duties and that the cleansing notice may be relied upon by shareholders intending to on-sell the newly issued shares.

No Excluded Information to Disclose Under Sections 708A(7) and 708A(8)

A key requirement of a valid cleansing notice is the company’s declaration regarding excluded information. Under sections 708A(7) and 708A(8) of the Corporations Act, the notice is effective only if the company confirms no information has been withheld from continuous disclosure due to confidentiality or a carve-out. Clarity has made this confirmation as of the notice date.

This declaration has legal significance, assuring recipients of the new shares and the broader market that Clarity is not withholding material price-sensitive information at the time the shares become eligible for on-sale. This standard but important representation underpins the cleansing notice regime and aligns with expectations for a compliant listed entity conducting a routine option exercise.

Role of Option Exercises in Clarity Pharmaceuticals' Capital Structure

Options are commonly included in the capital structures of clinical-stage pharmaceutical and biotechnology companies, often granted to employees, directors, advisers, and early investors as incentive compensation or consideration. Exercising options typically signals confidence in the company's prospects and adds shares to the register while potentially generating cash proceeds at the agreed exercise price.

Clarity did not disclose the exercise price or total cash proceeds from this option exercise in the announcement. Although the issuance of 110,000 shares represents a modest increase to Clarity's share capital, it may indicate positive holder sentiment. Investors should note the total share count has increased by this amount and monitor future option exercises as expiry dates approach across various tranches.

Clarity Pharmaceuticals' SAR Technology Platform and Clinical-Stage Radiopharmaceutical Pipeline

Clarity Pharmaceuticals is a clinical-stage radiopharmaceutical company focused on serious disease treatment, specifically developing targeted copper theranostics via its proprietary SAR Technology Platform. This platform aims to deliver copper-based radiopharmaceuticals to cancer cells precisely, enabling both diagnostic imaging (the "thera" component) and therapeutic treatment (the "nostics" component)—a dual-use approach gaining global attention in oncology.

The company's pipeline addresses cancer in children and adults, targeting significant unmet needs in paediatric oncology, where treatment options are limited, and adult cancer indications, where targeted precision medicine is rapidly advancing. While this update includes no clinical data or pipeline news, it reflects ongoing administrative operations as Clarity progresses through development stages. Investors should watch for separate announcements on trial results, regulatory interactions, and partnership developments.

Authorisation of the Notice by Executive Chairperson Dr Alan Taylor and Company Secretary Robert Vickery

The cleansing notice was signed and lodged by Robert Vickery as Company Secretary, following standard governance practices for regulatory filings. The company update was authorised for release by Dr Alan Taylor, Executive Chairperson of Clarity Pharmaceuticals, consistent with his role overseeing company direction and public communications.

The involvement of both the Company Secretary and Executive Chairperson highlights the procedural rigour required for even routine capital markets notices. For stakeholders, this authorisation chain provides assurance that the notice underwent appropriate governance review before market release. No management commentary or strategic guidance was included in this update.

Immediate Share Price Impact and Market Context for CU6

The immediate effect on share price was unclear from available information. The issuance of 110,000 shares via option exercise is a relatively small event within a clinical-stage biopharmaceutical company's total share capital, and cleansing notices of this nature are typically routine. However, option exercises may be viewed by some investors as a sign of holder confidence, though such interpretations should be cautious and are not confirmed by Clarity.

For investors following Clarity Pharmaceuticals, more significant near-term catalysts are likely to arise from clinical development progress rather than capital structure changes. Key upcoming milestones include clinical trial updates, data readouts from radiopharmaceutical studies, and announcements related to regulatory submissions or commercial partnerships. This cleansing notice does not alter the company’s clinical or commercial trajectory.

Investor Considerations Following This Update

This update primarily serves as a housekeeping notice confirming the legal status of newly issued shares. Long-term investors should focus on Clarity's advancement of its SAR Technology Platform through clinical trials, positive data generation, and progress toward regulatory approvals in Australia and internationally.

Investors may also track the remaining options outstanding, as future exercises could increase the share register over time. Understanding the full option schedule—including exercise prices and expiry dates—provides context for potential dilution. Clarity did not disclose remaining option details in this announcement. Interested parties should consult the company’s latest annual report, appendix 3Y filings, or meeting notices, which typically outline the company’s equity incentive arrangements.